Radicle Revive™: A Study Assessing the Impact of Health and Wellness Products on Menopausal-Related Health Issues Associated Health Outcomes and Related Health Outcomes

Official title

Radicle Revive™: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Menopausal-Related Health Issues Associated Health Outcomes and Related Health Outcomes

Overview

Radicle Revive™: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on menopausal-related health issues associated health outcomes.

Detailed description

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants will (1) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, (2) express acceptance in taking a product and not knowing its formulation until the end of the study, and Peri or Post menopausal women (3) regularly experiencing hot flashes and (4) Not taking a HRT medication.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants for 13 weeks. Participant reports of health indicators will be collected at enrollment and throughout the active period of study product usage. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Interventions

• Dietary supplement Revive Product Placebo Control
  Participants will use their Control as directed for a period of 12 weeks.
• Dietary supplement Revive Active Product 1
  Participants will use their Active product as directed for a period of 12 weeks.

Primary outcome measures

• Change in cognitive function [Time frame: 13 weeks]

Secondary outcome measures (8)

• Change in cognitive abilities [Time frame: 13 weeks]
• Change in feelings of anxiety [Time frame: 13 weeks]
• Hot Flash Interference over 12 weeks [Time frame: From Baseline to week 12 of product consumption.]
• Hot Flash Frequency [Time frame: From baseline to day 14 of product consumption.]
• Hot Flash Interference over 14 days [Time frame: From Baseline to day 14 of product consumption.]
• Hot Flash Frequency [Time frame: From baseline to week 12 of product consumption.]
• Hot Flash Intensity [Time frame: From baseline to week 12 of product consumption.]
• Hot Flash Intensity [Time frame: From baseline to day 14 of product consumption.]

Eligibility criteria

Inclusion

Participants must meet all the following criteria:

• Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
• Assigned sex at birth will determine sex-specific recruitment
• Resides in the United States
• Has the opportunity for at least 30% improvement in their primary health outcome
• Peri or Post Menopausal women who have been experiencing hot flashes for the past 3 months or longer
• Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion

Individuals who report any of the following during screening may be excluded from participation:

• Report being pregnant, trying to become pregnant, or breastfeeding
• Unable to provide a valid US shipping address and mobile phone number
• Reports current enrollment in another clinical trial
• Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• Unable to read and understand English at a 7th grade level
• Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
• NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
• Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
• Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
• Lack of reliable daily access to the internet
• Currently taking a HRT medication
• Pre-Menopausal women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Other

Study locations

United States · 1 center

• Radicle Science Inc. — Del Mar

Identifiers

NCT: NCT07548307 · RADX_P_2605_RGW

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗